GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...

BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...

On Thursday, genetics-led consumer healthcare company 23andMe Holding Co. (NASDAQ:ME) announced a business restructuring to ...

GSK delivered strong Trilogy sales, reaching $789 million for the quarter, positioning Theravance Biopharma Inc (NASDAQ:TBPH) ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Welcome to Natera’s 2024 Third Quarter Financial Results ...

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...

Theravance Biopharma ( (TBPH) ) has released its Q3 earnings. Here is a breakdown of the information Theravance Biopharma presented to its ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...